BIOLASE (NASDAQ:BIOL) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL) in a research note issued to investors on Friday. The brokerage set a “sell” rating on the medical technology company’s stock.

BIOLASE Price Performance

Shares of BIOL opened at $0.15 on Friday. The firm has a market capitalization of $4.92 million, a P/E ratio of 0.00 and a beta of 0.67. BIOLASE has a 12-month low of $0.13 and a 12-month high of $32.09. The company has a current ratio of 1.26, a quick ratio of 0.68 and a debt-to-equity ratio of 34.06. The firm has a fifty day moving average price of $0.15 and a 200-day moving average price of $0.81.

BIOLASE (NASDAQ:BIOL) last issued its earnings results on Thursday, March 21st. The medical technology company reported ($1.76) earnings per share (EPS) for the quarter. The company had revenue of $13.49 million for the quarter. BIOLASE had a negative net margin of 41.97% and a negative return on equity of 555.22%.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.